3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
No longer available
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Ipilimumab
123
pembrolizumab
101
Nivolumab
100
aldesleukin
89
Cyclophosphamide
85
fludarabine phosphate
64
Interleukin-2
58
Dacarbazine
57
3-ingenyl angelate
42
Vemurafenib
39
Temozolomide
39
Imiquimod
39
trametinib
37
sargramostim
37
Peripheral Blood Stem Cell Transplantation
36
incomplete Freund's adjuvant
35
dabrafenib
32
fludarabine
31
Radiotherapy
31
Aminolevulinic Acid
30
Bevacizumab
29
Carboplatin
28
Whole-Body Irradiation
25
Photochemotherapy
25
Paclitaxel
25
Filgrastim
25
Biopsy
25
Interferon-alpha
24
Cisplatin
23
Sorafenib
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
AM0010
×
Dermatologic
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled